Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 25

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 25
---
 not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is
not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly
update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances
or otherwise.

This prospectus and the documents
incorporated herein by reference also refer to estimates and other statistical data made by independent parties and by us relating to
market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned
not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future
performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

<div align='center'>2

ABOUT INMUNE BIO INC.</div>

We are a clinical-stage immunotherapy
company focused on reprogramming the patient’s innate immune system to treat disease. We do this by targeting four key cells of
the innate immune system, natural killer, or NK cells, and myeloid derived suppressor cells, or MDSC, hepatic stellate cells of the liver,
or HSC, and microglial cells of the central nervous system. NK cells are the body’s first line of defense due to their innate ability
to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support
molecules required to activate adaptive immune cells such as T-cells. NK cells play a key role in the immune-surveillance that prevents
people from getting cancer and in eliminating residual disease which may cause people to relapse after cytotoxic therapy. MDSC are myeloid
cells produced in the bone marrow, take up residence in the tumor microenvironment, the tissue associated with the cancerous cells, to
protect the tumor from immunological attack by the patient’s immune system. MDSC play a critical role in making the cancer resistant
to immunotherapy such as currently approved checkpoint inhibitors. Microglial cells are the primary immune cells of the central nervous
system responsible for protecting the neural unit of microglia, astrocytes, oligodendrocytes and neurons from infection. In the setting
of chronic inflammation,